Heart failure associated with small molecule tyrosine kinase inhibitors

被引:1
作者
Imran, Tasnim F. [1 ]
Shah, Rashesh [2 ]
Ha, Albert S. [1 ]
Thomas, Renjit [2 ]
Joseph, Jacob [1 ]
机构
[1] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brigham & Womens Hosp, Boston, MA 02120 USA
[2] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07103 USA
关键词
SORAFENIB; SUNITINIB; PHASE;
D O I
10.1016/j.ijcard.2016.01.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:110 / +
页数:2
相关论文
共 10 条
[1]   Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry [J].
Buchler, T. ;
Klapka, R. ;
Melichar, B. ;
Brabec, P. ;
Dusek, L. ;
Vyzula, R. ;
Abrahamova, J. .
ANNALS OF ONCOLOGY, 2012, 23 (02) :395-401
[2]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[3]   Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies [J].
Hahn, Virginia Shalkey ;
Lenihan, Daniel J. ;
Ky, Bonnie .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (02)
[4]   Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib [J].
Hochhaus, A. ;
Baccarani, M. ;
Deininger, M. ;
Apperley, J. F. ;
Lipton, J. H. ;
Goldberg, S. L. ;
Corm, S. ;
Shah, N. P. ;
Cervantes, F. ;
Silver, R. T. ;
Niederwieser, D. ;
Stone, R. M. ;
Dombret, H. ;
Larson, R. A. ;
Roy, L. ;
Hughes, T. ;
Mueller, M. C. ;
Ezzeddine, R. ;
Countouriotis, A. M. ;
Kantarjian, H. M. .
LEUKEMIA, 2008, 22 (06) :1200-1206
[5]   Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey [J].
Masini, Cristina ;
Sabbatini, Roberto ;
Porta, Camillo ;
Procopio, Giuseppe ;
Di Lorenzo, Giuseppe ;
Onofri, Azzurra ;
Buti, Sebastiano ;
Iacovelli, Roberto ;
Invernizzi, Roberta ;
Moscetti, Luca ;
Aste, Maria Giuseppina ;
Pagano, Maria ;
Grosso, Federica ;
Manenti, Anna Lucia ;
Ortega, Cinzia ;
Cosmai, Laura ;
Del Giovane, Cinzia ;
Conte, Pier Franco .
BJU INTERNATIONAL, 2012, 110 (05) :692-698
[6]   Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib [J].
Richards, Christopher J. ;
Je, Youjin ;
Schutz, Fabio A. B. ;
Heng, Daniel Y. C. ;
Dallabrida, Susan M. ;
Moslehi, Javid J. ;
Choueiri, Toni K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) :3450-3456
[7]   Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma [J].
Schmidinger, Manuela ;
Zielinski, Christoph C. ;
Vogl, Ursula M. ;
Bojic, Andja ;
Bojic, Marija ;
Schukro, Christoph ;
Ruhsam, Marquerite ;
Hejna, Michael ;
Schmidinger, Herwig .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5204-5212
[8]   Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors [J].
Strumberg, D ;
Richly, H ;
Hilger, RA ;
Schleucher, N ;
Korfee, S ;
Tewes, M ;
Faghih, M ;
Brendel, E ;
Voliotis, D ;
Haase, CG ;
Schwartz, B ;
Awada, A ;
Voigtmann, R ;
Scheulen, ME ;
Seeber, S .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :965-972
[9]   Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib [J].
Uraizee, Imran ;
Cheng, Susan ;
Moslehi, Javid .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (17) :1649-1650
[10]   Discovery and development of sorafenib: a multikinase inhibitor for treating cancer [J].
Wilhelm, Scott ;
Carter, Christopher ;
Lynch, Mark ;
Lowinger, Timothy ;
Dumas, Jacques ;
Smith, Roger A. ;
Schwartz, Brian ;
Simantov, Ronit ;
Kelley, Susan .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) :835-844